Lynparza (olaparib) vs Xeloda ()
Lynparza (olaparib) vs Xeloda ()
Lynparza (olaparib) is a targeted therapy known as a PARP inhibitor, primarily used for treating certain types of breast, ovarian, prostate, and pancreatic cancers in patients with specific genetic mutations (BRCA1 or BRCA2). Xeloda (capecitabine) is an oral chemotherapy drug that is a prodrug of 5-fluorouracil (5-FU) and is commonly used to treat breast, gastric, and colorectal cancers. The choice between Lynparza and Xeloda would depend on the cancer type, genetic makeup of the tumor, stage of cancer, patient's overall health, and previous treatments, making it crucial for patients to discuss with their oncologist to determine the most appropriate treatment plan.
Difference between Lynparza and Xeloda
| Metric | Lynparza (olaparib) | Xeloda (capecitabine) |
|---|---|---|
| Generic name | Olaparib | Capecitabine |
| Indications | BRCA-mutated advanced ovarian cancer, metastatic breast cancer, pancreatic cancer, prostate cancer | Metastatic colorectal cancer, metastatic breast cancer, gastric cancer |
| Mechanism of action | Poly (ADP-ribose) polymerase (PARP) inhibitor | Prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body |
| Brand names | Lynparza | Xeloda |
| Administrative route | Oral | Oral |
| Side effects | Anemia, nausea, fatigue, vomiting, respiratory infections | Diarrhea, hand-foot syndrome, nausea, vomiting, fatigue |
| Contraindications | Hypersensitivity to olaparib, pregnancy, breastfeeding | Hypersensitivity to capecitabine or fluorouracil, dihydropyrimidine dehydrogenase (DPD) deficiency |
| Drug class | PARP inhibitor | Antimetabolite, fluoropyrimidine |
| Manufacturer | AstraZeneca | Roche |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, also known by its generic name olaparib, is a targeted therapy known as a PARP inhibitor. It has been shown to be effective in the treatment of certain types of breast cancer. Specifically, Lynparza is approved for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Clinical trials have demonstrated that Lynparza significantly prolongs progression-free survival compared to standard chemotherapy in this patient population.
The efficacy of Lynparza in breast cancer was highlighted in the OlympiAD trial, which was a pivotal phase 3 study. In this trial, patients treated with Lynparza had a median progression-free survival of 7.0 months compared to 4.2 months for those receiving standard chemotherapy. Furthermore, the response rate to Lynparza was notably higher, indicating a greater proportion of patients experienced tumor shrinkage or disappearance.
Xeloda (Capecitabine) Efficacy in Breast Cancer
Xeloda, or capecitabine, is an oral chemotherapy medication that is metabolized into 5-fluorouracil (5-FU) in the body. It is used to treat breast cancer in various contexts, including metastatic breast cancer and adjuvant treatment following surgery in cases where additional chemotherapy is needed. In metastatic breast cancer, Xeloda has been shown to be effective as a single agent or in combination with other drugs, providing an important treatment option for patients who have previously received anthracycline- and/or taxane-based chemotherapy.
Studies have shown that Xeloda can improve overall survival and progression-free survival in certain breast cancer settings. For example, in the pivotal phase 3 trial comparing Xeloda to docetaxel in patients with metastatic breast cancer, Xeloda demonstrated a comparable efficacy to docetaxel, with some patients experiencing a more favorable safety profile. Additionally, Xeloda has been found to be effective in the adjuvant setting for patients with triple-negative breast cancer, especially when used in combination with other chemotherapeutic agents.
Regulatory Agency Approvals
Lynparza
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Xeloda
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Lynparza or Xeloda today
If Lynparza or Xeloda are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us